Aster Biospecialities Chemtecq Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 10-07-2024
- Paid Up Capital ₹ 5.00 M
as on 10-07-2024
- Company Age 14 Year, 2 Months
- Last Filing with ROC 31 Mar 2015
- Open Charges ₹ 33.80 M
as on 10-07-2024
- Revenue 1607.72%
(FY 2015)
- Profit 63.40%
(FY 2015)
- Ebitda 24304.54%
(FY 2015)
- Net Worth 301.14%
(FY 2015)
- Total Assets -5.92%
(FY 2015)
About Aster Biospecialities Chemtecq
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2015. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹3.38 Cr.
Geetaben Prajapati, Jagdish Prajapati, Dimpalben Patel, and One other member serve as directors at the Company.
- CIN/LLPIN
U01407GJ2010PTC062245
- Company No.
062245
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Sep 2010
- Date of AGM
30 Sep 2015
- Date of Balance Sheet
31 Mar 2015
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Kheda, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aster Biospecialities Chemtecq?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Geetaben Prajapati  | Director | 16-Aug-2016 | Current |
| Jagdish Prajapati | Director | 16-Aug-2016 | Current |
| Dimpalben Patel | Director | 12-Oct-2015 | Current |
| Rameshkumar Patel | Director | 09-Feb-2015 | Current |
Financial Performance and Corporate Structure Insights of Aster Biospecialities Chemtecq.
Aster Biospecialities Chemtecq Private Limited, for the financial year ended 2015, experienced significant growth in revenue, with a 1607.72% increase. The company also saw a substantial improvement in profitability, with a 63.4% increase in profit. The company's net worth Soared by an impressive increase of 301.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aster Biospecialities Chemtecq?
Unlock access to Aster Biospecialities Chemtecq's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Central Bank Of India Creation Date: 11 Oct 2013 | ₹1.69 Cr | Open |
Central Bank Of India Creation Date: 10 Oct 2013 | ₹1.69 Cr | Open |
How Many Employees Work at Aster Biospecialities Chemtecq?
Unlock and access historical data on people associated with Aster Biospecialities Chemtecq, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aster Biospecialities Chemtecq, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aster Biospecialities Chemtecq's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
